244 results about "Cerebral damage" patented technology

During childbirth, trauma to the infant can readily arise, ultimately resulting in fetal hypoxia, academia, and brain damage. Such unfavorable conditions can be best ascertained by real-time monitoring of the fetus' blood-oxygen level, heart rate monitoring, EKG and EEG waveforms. This invention describes a system of monitoring devices to implement such goals and maximize the potential welfare of the fetus. It furthermore allows the formation of a reference database that can correlate intrapartum events from prior births. The embodiments utilize a small-diameter sensor inserted into the birth canal through a tubular insertion rod. Through wire, fiber optics, and or using a radio frequency link, fetal monitor data can be analyzed, compared to existing data base, and or transmitted via internet. This patent details various apparatuses that allow important life-sign parameters of a fetus to be continuously monitored.

The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

The invention relates to an opto-acoustic brain function imaging method. The method realizes imaging of brain blood vessel structure distribution observation and function monitoring via the opto-acoustic tomographic image of the cortex blood vessels. Brain damage and cerebral hemorrhage variation degree can be monitored, and the parameters such as cerebral blood flow, brain oxygen consumption and brain oxygen saturation etc can be reflected via the blood vessel form distribution, blood diameter variation and opto-acoustic signal intensity variation of blood vessels. The laser generation component, acoustic signal acquisition component and computer among the devices realizing the mentioned method are electrically connected in turn. The rotary scanning mechanism is electrically connected with the computer. The sample fixation components are connected with the acoustic coupling components in turn. The invention is characterized by convenient operation and sensitive and quick performance, can make imaging analysis of blood vessels without damage, and then monitor brain function, which can thus provide imaging basis for brain function judgment.

The present invention relates to a method and kit for in vitro diagnosing a complex disease such as cancer, in particular, acute myeloid leukemia (AML), colon cancer, kidney cancer, prostate cancer; transient ischemic attack (TIA), ischemia, in particular stroke, hypoxia, hypoxic-ischemic encephalopathy, perinatal brain damage, hypoxic-ischemic encephalopathy of neotatals asphyxia; demyelinating disease, in particular, white-matter disease, periventricular leukoencephalopathy, multiple sclerosis, Alzheimer and Parkinson's disease; in a biological sample. For the diagnosis, use is made of measuring at least two different species of biomolecules and classifying the results by means of suitable classifier algorithms and other statistical procedures. With the present invention, a significant improvement of the reliability of e.g. expression profiles alone, are achieved. In other words, in a defined collective, an up to 100% accurate positive diagnosis could be achieved, which renders the method of the present invention superior over the prior art.

Methods of enabling locomotor control, postural control, voluntary control of body movements (e.g., in non-weight bearing conditions), and / or autonomic functions in a human subject having spinal cord injury, brain injury, or neurological neuromotor disease. In certain embodiments, the methods involve stimulating the spinal cord of the subject using an epidurally placed electrode array, subjecting the subject to physical training thereby generating proprioceptive and / or supraspinal signals, and optionally administering pharmacological agents to the subject. The combination of stimulation, physical training, and optional pharmacological agents modulate in real time electrophysiological properties of spinal circuits in the subject so they are activated by supraspinal information and / or proprioceptive information derived from the region of the subject where locomotor activity is to be facilitated.

The invention provides a synthetic polypeptide of Formula I′ (SEQ ID NO: 1):X1-X2-X3-R—X5-X6-X7-X8-X9-X10-X11-X12-X13  Ior an amide, an ester or a salt thereof, wherein X1, X2, X3, X5, X6, X7, X8, X9, X10, X11, X12 and X13 are defined herein. The polypeptides are agonist of the APJ receptor. The invention also relates to a method for manufacturing the polypeptides of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

The present invention provides a damaged part treatment composition for repairing a damaged part of a target tissue that includes a stem cell-conditioned medium obtained by culturing stem cells; a damaged part treatment method for repairing or restoring a damaged part of a target tissue that includes administering the damaged part treatment composition to a patient having the target tissue for the damaged part treatment composition in an amount therapeutically effective for repairing the damaged part of the target tissue; a method of treating cerebral infarction that includes administering the damaged part treatment composition to a cerebral infarct patient in an amount effective for repairing a damaged part of the brain; and a method of treating a CNS disease that includes administering, as a CNS disease treatment composition, the damaged part treatment composition to a CNS disease patient in a therapeutically effective amount.

A safety helmet system to minimize brain concussions for athletes experiencing impact loading. A housing incorporates a series of displaceable plates which are displaceable having a shear thickening fluid between the displaceable plates for rigidifying upon impact. The housing is connected on one end to a helmet and to shoulder pads on an opposing end.

Brain impairment, for example due to stroke, is corrected in order to improve body movement. An fNIRS device is positioned over the motor cortex of non-impaired individuals, and blood oxygen in locations of the brain is analyzed to determine brain activity corresponding to a particular body movement. The movements are statistically analyzed, and are compared with fNIRS data gathered from a movement impaired individual attempting the same movement. A weighted value corresponding to the desired brain activity is generated using the statistical analysis, and is graphically displayed to the movement impaired individual during the attempts. This produces a feedback loop relating to the movement which can be repeated to produce brain plasticity in the impaired individual to facilitate the movement. Additionally, correct brain activity can be used to cause the application of an electrical signal to muscles of the body to produce the desired movement.

The present invention relates to methods of diagnosing, monitoring, and assessing treatment effects for Aβ amyloidosis, early in the course of clinical disease or prior to the onset of brain damage and clinical symptoms. Methods of measuring the in vivo metabolism of biomolecules produced in the CNS in a subject are provided.

An alkyl ether derivative represented by the formula: wherein R1, R2, R3, R4, m and n are as defined in the specification, or salts thereof exhibits synergistically improved anti-hypoxic activity when combined with a compound having an acetylcholine esterase inhibitory activity. Therefore, the combination according to the present invention is useful as a method for improving cerebral function. Further, a pharmaceutical composition containing the compound relating to the combination according to the present invention is useful for treatment and prevention of dysfunction of cerebral acetylcholine neurons in the sequelae of cerebrovascular dementia, senile dementia, Alzheimer's disease and ischemic cerebral lesion and in the cerebral apoplexy or the memory impairment caused by selective neuronal death.

The present invention relates to the field of brain injuries. More specifically, the present invention provides methods and compositions useful in the diagnosis / prognosis / assessment of brain injuries. In a specific embodiment, a method for identifying which patients with traumatic brain injury (TBI) require a head computerized tomography (CT) scan for diagnosing acute intracranial pathology comprises the steps of (a) obtaining or collecting a sample from the patient; (b) measuring the levels of one or more biomarkers in the blood sample obtained from the patient, wherein the biomarkers comprise glial fibrillary acidic protein (GFAP), S100B, metallothionein 3 (MT3), neuron specific enolase (NSE) and intracellular adhesion molecule 5 (ICAM5); and (c) identifying the patient as requiring or not requiring a head CT scan based on the measured levels of one or more of biomarkers comprising GFAP, S100B, MT3, NSE and ICAM5.

The invention belongs to the technical field of medicine, and concretely relates to caffeoyl substituted pentacyclic triterpenoid derivatives as shown in a formula I and a purpose thereof in preparing medicaments or health products for preventing and treating brain injury and / or neurological dysfunction and / or cognitive dysfunction caused by cerebral ischemia, hypoglycemia and cerebral anoxia. Experiments verify that the derivatives is capable of protecting nerve cells under conditions of hypoglycemia and hypoxia, can substantially improve neurological damage induced by cerebral ischemia, and thus is expected to be developed as medicaments for preventing and treating the brain injury caused by the cerebral ischemia, the hypoglycemia and the cerebral anoxia as well as improving corresponding neuroethology functions.

The invention relates to an edaravone injection solution and a preparation method thereof. The edaravone injection solution contains vitamin C and glutathione, wherein the concentration of edaravone is 0.1%-0.2% (W / V), the concentration of the vitamin C is 0.1%-0.5% (W / V), and the concentration of glutathione is 1.0%-10.0% (W / V). Compared with the prior art, the edaravone injection solution has the beneficial effects that the edaravone, the vitamin C and the glutathione are reasonably matched to enable the three ingredients to exert a synergistic effect, so that the excellent oxidation property is given full play, the cerebral injury and the complications are well treated, and the stability is high.

An alkyl ether derivative represented by the formula:wherein R1, R2, R3, R4, m and n are as defined in the specification, or salts thereof exhibits synergistically improved anti-hypoxic activity when combined with a compound having an acetylcholine esterase inhibitory activity. Therefore, the combination according to the present invention is useful as a method for improving cerebral function. Further, a pharmaceutical composition containing the compound relating to the combination according to the present invention is useful for treatment and prevention of dysfunction of cerebral acetylcholine neurons in the sequelae of cerebrovascular dementia, senile dementia, Alzheimer's disease and ischemic cerebral lesion and in the cerebral apoplexy or the memory impairment caused by selective neuronal death.

The invention relates to the field of Chinese medicaments, in particular to a Chinese medicinal composition for preventing and treating ischemic brain injury, and a preparation method thereof. The Chinese medicinal composition for preventing and treating ischemic brain injury is an orally taken preparation prepared from extracts of raw astragalus roots, panax notoginseng, kudzuvine roots, baikal skullcap roots and gardenia serving as main active components, as well as pharmaceutical auxiliary materials. The preparation has obvious therapeutic effects on cerebral infarction convalescent symptoms of which the clinical manifestations are eye-mouth distortion, glossolalia, slobbering or hemiplegia, dark red tongue or yellow greasy tongue coating, weak or uneven pulse and the like.

The invention belongs to the medical rehabilitation equipment field, and relates to a digitlization simulation mirror image training system comprising a trainee interaction display, a trainee control platform, a host computer, a camera, sound equipment, digit mirror image training box hardware, a specially compiled space imagination training module, a basic motion training module, and a functional motion training module program system; the camera can film hand motion images; digitalized image mirror image equipment is formed by mirror image processing technology; the standard digitlization simulation mirror image treatment training system is provided; visual illusion and visual sense imagination can activate the cerebrum motion sense cortex zone, thus promoting limb motion functions and sense function recovery; optics imaging is converted into digit display, thus increasing mirror image treatment controllability and operationality, improving patient compliance, enriching mirror image training contents, regulating the training scheme enforcement procedure, and obtaining the optimized training effect; the digitlization simulation mirror image training system is suitable for rehabilitation training of hand function obstacles caused by brain damages, and finger cutting, affected limb aches, hand perception deletion or obstacles of hand operation patients.

The present invention relates to the identification and use of diagnostic markers related with brain damage, particularly, biomarkers independently selected from the group consisting of interleukin-17 (IL-17), Fas ligand (FasL), b nerve growth factor (bNGF), insulin growth factor binding protein 3 (IGFBP3), p55 tumour necrosis factor receptor (TNFR-1), growth-related oncogene alpha (GroA), interleukin-2 soluble receptor gamma (IL2RG) and combinations thereof, that are associated with the diagnosis, prognosis, or differentiation of stroke mimicking conditions and stroke in a subject.

The invention provides application of a cerebroside compound (cerebroside A and cerebroside B) extracted and prepared from termitomyces in the preparation of medicaments for treating brain injury after cerebral ischemia. Through pharmacological experiments, the invention confirms that the cerebroside compound has significant therapeutic effect on ischemic brain injury, can permeate blood-brain barriers, reduces the area of cerebral infarction caused by cerebral ischemia, alleviates cerebral edema, reduces neuronal cell death, simultaneously promotes the recovery of motor and cognitive function after stroke, and reduces stroke mortality. The invention develops novel medicament use of the cerebroside compound, and provides a novel therapeutic medicament for treating stroke diseases.

The present invention relates to novel biomarkers for predicting the likelihood of inflammation-related brain injury in preterm born infants, using a plurality of endogenous target metabolites selected from the group consisting of acyl carnitins, diacylphosphatidylcholines, acyl-alkylphosphatidylchoines, lysophosphatidylcholines and amino acids.

The present invention provides a benzimidazole compound represented by Formula (I)wherein X1 is oxygen or carbonyl, and R1 is a furan ring having 1 to 3 substituents or a pyrrole ring that may have 1 to 3 substituents; excluding compounds represented by Formula (I) wherein at least one of the substituents is a phosphoric acid group or a phosphoric ester group; or a salt thereof. The benzimidazole compound or salt thereof has excellent prostaglandin synthase inhibitory activity, and is useful as an agent for preventing and / or treating diseases in which prostaglandin D2 or metabolites thereof participates, such as allergic and inflammatory diseases, and as inhibitor for the exacerbation of Alzheimer's disease or cerebral damage.

Provided is a method of diagnosing and / or monitoring mild traumatic brain injury (mTBI) or concussion in a subject. The method comprises determining a level of at least one miRNA in a saliva sample from the subject. Also provided is a sensor element, a detection system, composition and a kit for diagnosing and / or monitoring TBI, and a method of determining an appropriate treatment for a subject with suspected mTBI or concussion.

The invention relates to a method for establishing an artery ischemia model of a brain of a rhesus monkey and an evaluation method. The constructing method adopts the mode of directly puncturing femoral arteries of an experimental monkey to perform the intravascular interventional operation under the direct view of a digital subtraction angiography, and establishes the chronic cerebral infarctionprimate model by using a micro-catheter to block the arteries in the brain of the experimental monkey and controlling ischemia time. The model is a quite reasonable cerebral ischemia-reperfusion animal model, and the pathological characteristics of the monkey cerebral injury model established by the method are similar to clinical manifestation; and moreover, the model is stable and reliable and issuitable for all kinds of curing therapeutic research and related basic research.

The present invention provides the GST fusion expression and application of a kind of conotoxin MVII A gene. GST-CTX MVII A recombinant fusion protein is cloned and expressed in colibacillus, and through GST affinity chromatography purified GST-CTX MVII A fusion protein is obtained. The fusion protein the present invention obtains may be applied in preparing medicine for treating intractable painof cancer and AIDS patient in the late stage, preparing analgesic for treating post-operation acute pain, pain of burn, biliary colic, intractable neuralgia, etc., and preparing medicine with nerve protecting function for treating cerebral ischemia and cerebral damage. The obtained fusion protein has relatively great molecular weight and relatively long half life in body and may be enzyme incisedto obtain active omiga-conotoxin MVII A small peptide for direct medicine development.

The invention encompasses intravenous pharmaceutical compositions containing omega-3 fatty acids and methods of treating traumatic brain injury, traumatic spinal cord injury and / or stroke using these pharmaceutical compositions.

The invention belongs to the technical field of medicines, and relates to a novel method for preparing shiny-leaved yellowhorn total saponins from shiny-leaved yellowhorn and an application of the shiny-leaved yellowhorn total saponins. According to the method, a coarse extract of the shiny-leaved yellowhorn is directly separated and purified by a macroporous resin method to obtain shiny-leaved yellowhorn total saponins; the yield of the total saponins is over 5 percent, and the content of the total saponins in a product is over 60 percent and far higher than that in products prepared by other processes. The prepared shiny-leaved yellowhorn total saponins can be applied to preparation of medicines or health-care products for preventing and treating memory deterioration, hypophrenia and cranial nerve injury caused by neurodegenerative diseases and acute and chronic cerebral injury diseases, and can be used for treating cerebral diseases caused by alzheimer disease, acute disease and subacute stage of cerebral arterial thrombosis, vascular dementia and other ischemia and hypoxia of neurodegenerative diseases and acute and chronic cerebral injury diseases.

The present invention belongs to the field of pharmaceutical technology and relates to transdermal Ligustrazine plaster and its preparation. It has Ligustrazine phosphate or Ligustrazine as active medicinal component and consists of medicine storing back, adhering layer, release controlling film, back lining layer and protective layer. It is superior to available Ligustrazine preparation forms inmedicine releasing are, transdermal rate and lasting release time, and has the features of determined curative effect, stable quality, high safety, etc. Animal experiments show that the plaster can retard the effect of ischemic to cerebral damage, inhibit thrombosis caused by tissue damage, prevent and treat cerebral embolism and maintain balanced medicine density in blood for 24 hr; and has light irritation to skin, no irritability and no toxic reaction.

The present invention provides a novel 11-step enantioselective approach to the natural product hyperforin, which enables access to a wide variety of hyperforin analogs. The present invention also provides pharmaceutical compositions comprising inventive hyperforin analogs. Hyperforin analogs synthesized using the present synthetic method are envisionsed useful in the treatment of various conditions, including, but not limited to, depression and conditions characterized by depression, inflammatory skin conditions, diabetes, asthma, chronic obstructive pulmonary disease (COPD), kidney disorders, and ischemic brain damage.

The invention discloses a comprehensive magnetic resonance imaging device. According to the invention, the cerebral function imaging, the MRI perfusion weighted imaging and the magnetic resonance diffusion imaging are united, so that the assessment for the cerebral injury caused by motor neuron disease and Parkinson disease is assisted, a beneficial judging basis is supplied for illness state judgment, and the accuracy rate of disease judgment is increased; an ALS (amyotrophic lateral sclerosis) patient is accompanied with FTD (frontal temporal dementia), so that the detection means, such as cortex thickness, also is beneficial to the disease diagnose and research; functional magnetic resonance imaging (fMRI) and diffusion tensor imaging techniques have strong complementarity; the combination of the functional magnetic resonance imaging and diffusion tensor imaging techniques has a wide application prospect in neurosciences research; unique brain structure and function information can be supplied.